Progress in drug therapy for COVID-19 infection

Abstract

Abstract: The novel coronavirus pneumonia caused by COVID-19 has emerged in Wuhan at the end of Dec. 2019, and then has spread across our country. To date, no specific therapy against the new virus is available. The clinical efficacy of some antiviral drugs, such as remdesivir, chloroquine phosphate, abidor and so on are still need to be further verified. In this article the recent progress on drug therapy for COVID-19 infection is reviewed.

Key words: novel coronavirus, antiviral therapy, antiviral peptide, antibody

CLC Number:

R978.7

LIU Fang-yuan, SU Xiu-lan. Progress in drug therapy for COVID-19 infection[J]. Basic & Clinical Medicine, 2020, 40(10): 1416-1420.

References

[1] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382: 727-733.
[2] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronavirus[J]. Nat Rev Microbiol, 2019,17:181-192.
[3] Zhou P, Yang XL, Wang XG, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[J]. bioRxiv, 2020, 2020.01.22.914952.doi:10.1002/jmv.25725.
[4] Xia J, Tong J, Liu M, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection[J]. J Med Virol, 2020, doi: 10.1002/jmv.25725.
[5] Li Y, Zhang J, Wang N, et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening[J]. bioRxiv, 2020.doi:10.1101/2020.01.28.9922922.
[6] Xu Z, Peng C, Shi Y, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation[J]. bioRxiv, 2020.doi:10.1011/2020.01.27.921627.
[7] Zhou N, Pan T, Zhang J, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respira-tory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)[J]. J Biol Chem, 2016, 291: 9218-9132.
[8] Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus[J]. Antiviral Res, 2015, 115:9-16.
[9] De Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture[J]. Antimicrob Agents Chemother, 2014, 58: 4875-4884.
[10] Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus[J]. Proc Natl Acad Sci U S A, 2004, 101: 10012-10017.
[11] Hoffmann M, Kleine-Weber H, Christain D, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells[J]. bioRxiv, 2020.doi:10.1011/2020.01.31.929042.
[12] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017. doi: 10.1126/scitranslmed.aal3653.
[13] Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19[J]. N Engl J Med, 2020. doi: 10.1056/NEJMoa2015301.
[14] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395: 1569-1578.
[15] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroqu-ine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial[J]. Int J Antimicrob Agents, 2020. doi: 10.1016/j.ijantimicag.2020.105949.
[16] Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis[J]. Lancet, 2020. doi: 10.1016/S0140-6736(20)31180-6.
[17] Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor[J]. Nat Commun, 2014. doi: 10.1038/ncomms4067.
[18] Zabrodskaya YA, Lebedev DV, Egorova MA, et al. The amyloidogenicity of the influenza virus PB1-derived peptide sheds light on its antiviral activity[J]. Biophys Chem, 2018, 234:16-23.
[19] Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors[J]. Science, 2020, 368:409-412.
[20] Ju B, Zhang Q, Ge X, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. bioRxiv, 2020.doi:10.1101/2020.03.21.990770.
[21] Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J]. Cell, 2020. doi: 10.1016/j.cell.2020.05.025.
[22] Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2[J]. Nature, 2020. doi: 10.1038/s41586-020-2381-y.
[23] Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2[J]. Science, 2020. doi: 10.1126/science.abc2241.
[24] Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2020. doi: 10.1016/j.phymed.2020.153242.
[25] Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment[J]. Biosci Trends, 2020, 14:64-68.
[26] Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet, 2020. doi: 10.1016/S0140-6736(20)31208-3.